A Study of AeroVanc for the Treatment of MRSA Infection in CF Patients
This study is a multi-center, randomized phase III study to evaluate the clinical effectiveness of AeroVanc in persistent MRSA in patients with Cystic Fibrosis.
- Cystic Fibrosis
- Eligible Ages
- Over 6 Years
- Eligible Genders
- Accepts Healthy Volunteers
- Subjects ≥ 6 years of age at time of Informed Consent Form (ICF) or Assent Form signing.
- Confirmed diagnosis of CF, determined by having clinical features consistent with the CF phenotype, plus one of the following:
- Positive sweat chloride test (value ≥ 60 mEq/L),
- Genotype with 2 mutations consistent with CF (i.e., a mutation in each of the cystic fibrosis transmembrane conductance regulator [CFTR] genes).
- Positive sputum culture or a throat swab culture for MRSA at Screening.
- In addition to the Screening sample, have at least 2 prior sputum or throat swab cultures positive for MRSA, of which at least 1 sample is more than 6 months prior to Screening. At least 50% of all MRSA cultures (sputum or throat swab culture) collected from the time of the first positive culture (in the previous 1 year) must have tested positive for MRSA. (Note: Screening sample may count towards 50% positive count)
- Forced expiratory volume in 1 second (FEV1) ≥ 30% and ≤ 90% of predicted that is normal for age, gender, race, and height, using the Global Lung Function Initiative (GLI) equation.
- At least 1 episode of acute pulmonary infection treated with non-maintenance antibiotics within 12 months prior to the Baseline visit. (Initiation of treatment with intermittent inhaled anti-Pseudomonal therapy will not qualify as treatment with non-maintenance antibiotics).
- If female of childbearing potential, an acceptable method of contraception must be used during the study and must be combined with a negative pregnancy test obtained during Screening; sexually active male subjects of reproductive potential who are non-sterile (i.e., male who has not been sterilized by vasectomy for at least 6 months, and were not diagnosed with infertility through demonstration of azoospermia in a semen sample and/or absence of vas deferens through ultrasound) must be willing to use a barrier method of contraception, or their female partner must use an acceptable method of contraception, during the study.
For purposes of this study, the Sponsor defines "acceptable methods of contraception" as:
1. Oral birth control pills administered for at least 1 monthly cycle prior to administration of the study drug.
2. A synthetic progestin implanted rod (eg, Implanon®) for at least 1 monthly cycle prior to the study drug administration but not beyond the 4th successive year following insertion.
3. Intrauterine devices (IUDs), inserted by a qualified clinician for at least 1 monthly cycle prior to study drug administration.
4. Medroxyprogesterone acetate (eg, Depo-Provera®) administered for a minimum of 1 monthly cycle prior to administration of the study drug and continuing through 1 month following study completion.
5. Hysterectomy or surgical sterilization.
7. Double barrier method (diaphragm with spermicidal gel or condoms with contraceptive foam).
NOTE: For subjects prescribed Orkambi: Orkambi may substantially decrease hormonal contraceptive exposure, reducing the effectiveness and increasing the incidence of menstruation-associated adverse reactions. Hormonal contraceptives, including oral, injectable, transdermal, and implantable, should not be relied upon as an effective method of contraception when co-administered with Orkambi.
8. Able and willing to comply with the protocol, including availability for all scheduled study visits and able to perform all techniques necessary to use the AeroVanc inhaler and measure lung function.
9. Agree not to smoke during any part of the clinical trial (Screening visit through end of study).
10. Subjects with a P. aeruginosa co-infection must either be stable on a regular suppression regimen of inhaled antibiotics or must be, in the opinion of the Investigator, stable despite the lack of such treatment.
- Use of anti-MRSA treatments prescribed as maintenance therapy (intravenous [IV] or inhaled treatment within 28 days; oral treatment within 14 days) prior to the Baseline visit.
- Use of non-maintenance antibiotic for pulmonary infection or extrapulmonary MRSA infection (IV or inhaled antibiotic within 28 days; oral antibiotic within 14 days) prior to the Baseline visit.
- History of previous allergies or sensitivity to vancomycin, or other component(s) of the study drug or placebo except for a history of red-man syndrome.
- Inability to tolerate inhaled products.
- First time sputum culture or throat swab culture yielding B. cepacia, or nontuberculous Mycobacteria in the previous 6 months to Screening.
- History of lung or other solid organ transplantation or currently on the list to receive lung or other solid organ transplantation.
- Resistance to vancomycin at Screening (vancomycin resistant Staphylococcus aureus [VRSA], or vancomycin intermediate resistant Staphylococcus aureus [VISA], with minimum inhibitory concentration [MIC] ≥ 8 μg/mL).
- Oral corticosteroids in doses exceeding 10 mg prednisone per day or 20 mg prednisone every other day, or equipotent doses of other corticosteroids.
- Changes in antimicrobial, bronchodilator, anti-inflammatory or corticosteroid medications within 14 days, or changes in CFTR modulators within 28 days, prior to the Baseline visit.
- Abnormal laboratory findings or other findings or medical history at Screening that, in the Investigator's opinion, would compromise the safety of the subject or the quality of the study data.
- Inability to tolerate inhalation of a short acting beta2 agonist
- SpO2 <90% at Screening.
- Changes in physiotherapy technique or physiotherapy scheduled within 1 week of the Baseline visit.
- Administration of any investigational drug or device within 4 weeks prior to the Screening visit and during the study
- Female with positive pregnancy test result during Screening, pregnant (or intends to become pregnant), lactating or intends to breastfeed during the study.
- Renal insufficiency, defined as creatinine clearance < 50 mL/min using the Cockcroft-Gault equation for adults or Schwartz equation for children at the Screening visit.
- Abnormal liver function, defined as ≥ 4x upper limit of normal (ULN), of serum aspartate aminotransferase (AST) or serum alanine aminotransferase (ALT), or known cirrhosis at Screening.
- Diagnosed with clinically significant hearing loss.
- History of positive result for human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV).
- Planned hospitalizations for prophylaxis antibiotic treatment within 28 days prior to Baseline visit or during the double-blind period (Period 1).
- Phase 3
- Study Type
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Vancomycin inhalation powder
|30 mg twice daily (BID)||
Placebo inhalation powder
|Matching placebo inhaled twice daily (BID)||
Mobile, Alabama 36608
Phoenix, Arizona 85016
Little Rock, Arkansas 72205
Long Beach, California 90806
Los Angeles, California 90027
Los Angeles, California 90033
Sacramento, California 95817
Aurora, Colorado 80045
Denver, Colorado 80206
Connie St Clair
Gainesville, Florida 32610
Hollywood, Florida 33021
Norma Jean Barton
Jacksonville, Florida 32207
Miami, Florida 33136
Orlando, Florida 32803
Orlando, Florida 32806
Orlando, Florida 32827
Saint Petersburg, Florida 33701
Atlanta, Georgia 30342
Augusta, Georgia 30912
Glenview, Illinois 60025
Morton Grove, Illinois 60053
Indianapolis, Indiana 46202
Iowa City, Iowa 52242
Kansas City, Kansas 66160
Wichita, Kansas 67214
Louisville, Kentucky 40202
Molly Harper, BA, CCRC
Portland, Maine 04102
Boston, Massachusetts 02115
Ann Arbor, Michigan 48109
Detroit, Michigan 48201
Minneapolis, Minnesota 55404
Kansas City, Missouri 64108
Saint Louis, Missouri 63104
Saint Louis, Missouri 63110
Omaha, Nebraska 68198
Morristown, New Jersey 07960
New Brunswick, New Jersey 08901
Albuquerque, New Mexico 87131
Albany, New York 12208
New Hyde Park, New York 11042
New York, New York 10032
Durham, North Carolina 27710
Winston-Salem, North Carolina 27157
Akron, Ohio 44308
Cincinnati, Ohio 45229
Cleveland, Ohio 44106
Columbus, Ohio 43205
Dayton, Ohio 45404
Toledo, Ohio 43606
Oklahoma City, Oklahoma 73104
Jodie Fox, RN
Oklahoma City, Oklahoma 73112
Portland, Oregon 97239
Hershey, Pennsylvania 17033
Philadelphia, Pennsylvania 19104
Pittsburgh, Pennsylvania 15224
Charleston, South Carolina 29425
Sioux Falls, South Dakota 57105
Memphis, Tennessee 38103
Austin, Texas 78723
Dallas, Texas 75235
Fort Worth, Texas 76104
Houston, Texas 77030
San Antonio, Texas 78229
San Antonio, Texas 78229
Tyler, Texas 75708
Salt Lake City, Utah 84132
Colchester, Vermont 05446
Charlottesville, Virginia 22908
Christie L. Aderholt, RN, BSN
Norfolk, Virginia 23507
Seattle, Washington 98105
Morgantown, West Virginia 26506
Tammy Clark, RN, BSN
Milwaukee, Wisconsin 53226
- NCT ID
- Savara Inc.
Study ContactJessica Jackson
This is a Phase III, randomized, multicenter, double-blind, placebo-controlled, parallel-group study to examine the safety and efficacy of AeroVanc in the treatment of persistent Methicillin resistant Staphylococcus aureus (MRSA) lung infection in patients diagnosed with cystic fibrosis (CF). After the Screening period to confirm study eligibility, subjects will be randomly assigned in a blinded fashion to receive either AeroVanc 30 mg twice daily (BID), or placebo BID (1:1 active to placebo) by inhalation for 24 weeks or 3 dosing cycles (Period 1). Upon completion of Period 1, subjects will receive open-label AeroVanc 30 mg BID for an additional 24 weeks or 3 dosing cycles (Period 2), to evaluate long-term safety of AeroVanc. A dosing cycle is defined as 28 days of treatment followed by 28 days of observation.
Subjects on a 28-day cyclical on/off anti-Pseudomonal antibiotic regimen will enter the Screening period at a time such that the Baseline visit coincides with the end of their anti-Pseudomonas antibiotic cycle. Study drug will thereby be administered during the off-cycle, and subjects can then resume anti-Pseudomonal therapy during the 28-day observation period. Subjects continuing alternating anti-Pseudomonal therapy can continue their treatment during the study drug administration, and observation period.
The primary and secondary analyses will be conducted in subjects ≤21 years old. Subjects >21 years old will be analyzed separately as a supportive analysis.